CPH set to expand in $300M Latin American CBD market
Finfeed Archived Jun 04, 2021
The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will allow for distribution of Creso Pharma Limited's (ASX: CPH, FRA: 1X8) hemp derived therapeutic products sold under the cannaQIX® and CannaDOL brands into Ecuador.
Bod Australia continues to break sales records
Finfeed Archived May 10, 2021
Bod Australia (ASX: BDA) today announced its highest ever monthly sales for its medicinal cannabis prescription products. BDA attributes its current growth to its Australia wide clinical study to test the efficacy of MediCabilis™ when prescribed for conditions including anxiety, insomnia, and Post Traumatic Stress Disorder (PTSD).
Can BDA’s medical cannabis product treat long-COVID symptoms?
Finfeed Archived Mar 18, 2021
Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.
Creso enters the growing CBD market in sport and recreation
Finfeed Archived Mar 09, 2021
Today, Creso Pharma Limited (ASX:CPH, FRA:1X8) announced a Letter of Interest (LOI) which marks its entry into the CBD market for sport and recreation; an industry whose global valuation is estimated at US$22Bn by 2022 and C$220m in Canada alone.
CPH deliver Financials and Confirms US Cannabis Market Entry
Next Investors Mar 01, 2021
Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.
NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await
Finfeed Archived Dec 21, 2020
Neurotech International Ltd (ASX: NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.